EBITDA: Income before interest, taxes, depreciation and amortization.
Jazz Pharmaceuticals PLC (JAZZ) had EBITDA of $235.76M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
$1.13B |
|
$251.41M |
|
$128.88M |
|
$997.23M |
|
$1.07B |
|
$57.51M |
|
$-48.47M |
|
$9.04M |
|
$9.04M |
|
$251.46M |
|
$251.41M |
|
$251.41M |
|
$251.46M |
|
$57.51M |
|
|
EBITDA |
$235.76M |
60.70M |
|
61.61M |
|
$4.14 |
|
$4.08 |
|
| Balance Sheet Financials | |
$3.76B |
|
$188.91M |
|
$7.60B |
|
$11.36B |
|
$2.27B |
|
$4.33B |
|
$5.12B |
|
$7.40B |
|
$3.96B |
|
$-2.43B |
|
$3.96B |
|
60.74M |
|
| Cash Flow Statement Financials | |
$993.25M |
|
$-1.14B |
|
$-948.82M |
|
$2.41B |
|
$1.33B |
|
$-1.09B |
|
$220.28M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.65 |
|
-- |
|
-- |
|
0.52 |
|
1.35 |
|
88.56% |
|
5.11% |
|
5.11% |
|
-- |
|
0.80% |
|
22.33% |
|
$93.18M |
|
-- |
|
-- |
|
-- |
|
0.10 |
|
0.27 |
|
1.47 |
|
61.09 |
|
6.35% |
|
-10.33% |
|
2.21% |
|
3.03% |
|
$65.18 |
|
$1.51 |
|
$16.12 |
|